Structure Therapeutics is trading 6.09% up in pre-market at $42.84 after positive clinical data for oral obesity treatments aleniglipron and ACCG-2671.
- September 8, 2026 data showed 180 mg aleniglipron produced up to 16.2% body-weight loss at 72 weeks, with fewer than 5% discontinuing due to adverse events.
- The update supports the ongoing Phase 3 ACCOMPLISH program.
- The rebound follows a 14.70% decline on September 8 despite broadly cautious market sentiment; the company-specific clinical update is the clearest catalyst.